135 related articles for article (PubMed ID: 23357461)
1. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?
Creaney J; Dick IM; Dare H; Demelker Y; Nowak AK; Musk AW; Robinson BW
Lung Cancer; 2013 Apr; 80(1):39-44. PubMed ID: 23357461
[TBL] [Abstract][Full Text] [Related]
2. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
[TBL] [Abstract][Full Text] [Related]
3. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
[TBL] [Abstract][Full Text] [Related]
4. Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos.
Gube M; Taeger D; Weber DG; Pesch B; Brand P; Johnen G; Müller-Lux A; Gross IM; Wiethege T; Weber A; Raithel HJ; Kraus T; Brüning T
Arch Toxicol; 2011 Mar; 85(3):185-92. PubMed ID: 20737138
[TBL] [Abstract][Full Text] [Related]
5. Utility of mesothelin, L1CAM and Afamin as biomarkers in primary ovarian cancer.
Aktas B; Kasimir-Bauer S; Wimberger P; Kimmig R; Heubner M
Anticancer Res; 2013 Jan; 33(1):329-36. PubMed ID: 23267165
[TBL] [Abstract][Full Text] [Related]
6. Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case-control study.
Roe OD; Creaney J; Lundgren S; Larsson E; Sandeck H; Boffetta P; Nilsen TI; Robinson B; Kjaerheim K
Lung Cancer; 2008 Aug; 61(2):235-43. PubMed ID: 18281122
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of serum mesothelin in malignant and benign ovarian masses.
Ibrahim M; Bahaa A; Ibrahim A; El Hakem AA; Abo-El Noor A; El Tohamy U
Arch Gynecol Obstet; 2014 Jul; 290(1):107-13. PubMed ID: 24445964
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of soluble mesothelin-related peptide as a diagnostic marker of malignant pleural mesothelioma effusions: its contribution to cytology.
Canessa PA; Franceschini MC; Ferro P; Battolla E; Dessanti P; Manta C; Sivori M; Pezzi R; Fontana V; Fedeli F; Pistillo MP; Roncella S
Cancer Invest; 2013 Jan; 31(1):43-50. PubMed ID: 23249166
[TBL] [Abstract][Full Text] [Related]
9. Impact of renal failure on the tumor markers of mesothelioma, N-ERC/mesothelin and osteopontin.
Shiomi K; Shiomi S; Ishinaga Y; Sakuraba M; Hagiwara Y; Miyashita K; Maeda M; Suzuki K; Takahashi K; Hino O
Anticancer Res; 2011 Apr; 31(4):1427-30. PubMed ID: 21508397
[TBL] [Abstract][Full Text] [Related]
10. Serum and pleural fluid biomarkers for mesothelioma.
Creaney J; Robinson BW
Curr Opin Pulm Med; 2009 Jul; 15(4):366-70. PubMed ID: 19417672
[TBL] [Abstract][Full Text] [Related]
11. A binding domain on mesothelin for CA125/MUC16.
Kaneko O; Gong L; Zhang J; Hansen JK; Hassan R; Lee B; Ho M
J Biol Chem; 2009 Feb; 284(6):3739-49. PubMed ID: 19075018
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
Bruno F; Baratti D; Martinetti A; Morelli D; Sottotetti E; Bonini C; Guaglio M; Kusamura S; Deraco M
Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
[TBL] [Abstract][Full Text] [Related]
13. Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumor volume, clinical stage and changes in tumor burden.
Creaney J; Francis RJ; Dick IM; Musk AW; Robinson BW; Byrne MJ; Nowak AK
Clin Cancer Res; 2011 Mar; 17(5):1181-9. PubMed ID: 21177406
[TBL] [Abstract][Full Text] [Related]
14. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer.
Hassan R; Remaley AT; Sampson ML; Zhang J; Cox DD; Pingpank J; Alexander R; Willingham M; Pastan I; Onda M
Clin Cancer Res; 2006 Jan; 12(2):447-53. PubMed ID: 16428485
[TBL] [Abstract][Full Text] [Related]
15. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma.
Tajima K; Hirama M; Shiomi K; Ishiwata T; Yoshioka M; Iwase A; Iwakami S; Yamazaki M; Toba M; Tobino K; Sugano K; Ichikawa M; Hagiwara Y; Takahashi K; Hino O
Anticancer Res; 2008; 28(6B):3933-6. PubMed ID: 19192652
[TBL] [Abstract][Full Text] [Related]
16. Difference in mesothelin-binding ability of serum CA125 between patients with endometriosis and epithelial ovarian cancer.
Sasaki A; Akita K; Ito F; Mori T; Kitawaki J; Nakada H
Int J Cancer; 2015 Apr; 136(8):1985-90. PubMed ID: 25197000
[TBL] [Abstract][Full Text] [Related]
17. Mesothelin and kidney function--analysis of relationship and implications for mesothelioma screening.
Boudville N; Paul R; Robinson BW; Creaney J
Lung Cancer; 2011 Sep; 73(3):320-4. PubMed ID: 21333373
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma.
Pantazopoulos I; Boura P; Xanthos T; Syrigos K
Eur Respir J; 2013 Mar; 41(3):706-15. PubMed ID: 22835614
[TBL] [Abstract][Full Text] [Related]
19. Circulating CA125 in patients with peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion.
Baratti D; Kusamura S; Martinetti A; Seregni E; Oliva DG; Laterza B; Deraco M
Ann Surg Oncol; 2007 Feb; 14(2):500-8. PubMed ID: 17151789
[TBL] [Abstract][Full Text] [Related]
20. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
Nicolaides NC; Schweizer C; Somers EB; Wang W; Fernando S; Ross EN; Grasso L; Hassan R; Kline JB
Cancer Biol Ther; 2018 Jul; 19(7):622-630. PubMed ID: 29652548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
